KRAS and metastatic neoplasm: Regardless of type and location, KRAS mutations play a prognostic role and, when grouped together, patients with KRAS mutated metastatic disease have a higher mortality rate (18.5% vs. 34%) and a shorter survival (14 months vs. 23.5 months) than wt ones [25].